MICONAZOLE 7 COMBINATION PACK
Clinical safety rating: safe
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
Miconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and leakage of cellular contents, resulting in fungal cell death.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways; the specific cytochrome P450 enzymes have not been fully characterized, but it is known to inhibit CYP2C9, CYP3A4, and CYP2C19. |
| Excretion | Miconazole is primarily metabolized in the liver, with metabolites and unchanged drug excreted in feces (50-70%) and urine (10-20%). Biliary excretion is a minor route. |
| Half-life | Terminal elimination half-life is approximately 24-30 hours after systemic absorption. Clinically, this supports once-daily dosing for the vaginal route. |
| Protein binding | Approximately 90-95% bound to serum albumin. |
| Volume of Distribution | Vd is about 20-25 L/kg, indicating extensive tissue distribution and penetration into vaginal tissues. |
| Bioavailability | Vaginal administration: systemic bioavailability is low (<1-3%) due to limited absorption through vaginal mucosa; topical absorption is negligible. |
| Onset of Action | For vaginal administration, symptomatic relief of vulvovaginal candidiasis typically begins within 24-48 hours after first dose. |
| Duration of Action | Therapeutic effect lasts for up to 7 days after completion of the 7-day vaginal regimen; clinical cure rates exceed 80%. |
Miconazole 200 mg vaginal suppository once daily at bedtime for 7 days, plus miconazole 2% cream applied intravaginally once daily at bedtime for 7 days.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not recommended in pediatric patients <12 years. |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
| FDA category | Human |
| Breastfeeding | Minimal systemic absorption; M/P ratio not established. It is considered compatible with breastfeeding due to negligible transfer into breast milk after topical/vaginal administration. Caution with application to nipple area to avoid infant oral exposure. |
| Teratogenic Risk | Miconazole is an azole antifungal. Systemic absorption after vaginal application is minimal (approximately 1.4%). No increased risk of major birth defects has been observed in large cohort studies, although animal studies (high oral doses) show some fetotoxicity. First trimester: low risk generally accepted; second and third trimesters: safe for topical/vaginal use. Avoid high-dose systemic therapy in pregnancy. |
■ FDA Black Box Warning
None.
| Common Effects | vaginal yeast infections |
| Serious Effects |
Known hypersensitivity to miconazole or any component of the formulation; hepatic impairment (for systemic use).
| Precautions | Hypersensitivity reactions including anaphylaxis have been reported. Discontinue if irritation or sensitization occurs. Contains mineral oil, which may cause latex products to fail. Use with caution in patients with known hypersensitivity to imidazoles. Not for oral, ophthalmic, or intravaginal administration if using topical formulation. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Monitor for local irritation or hypersensitivity. In cases of recurrent infection, rule out gestational diabetes or other immunosuppressive conditions. |
| Fertility Effects | No adverse effects on fertility reported with topical/vaginal use. Systemic high doses in animal studies showed impaired fertility, but not relevant at clinical doses for vaginal candidiasis. |